Novo Nordisk's FREHEMGO® Wins EU Nod for Haemophilia A, Expanding Dosing Flexibility

  • European Commission approves FREHEMGO® (denecimig) for haemophilia A, offering monthly, bi-weekly, or weekly dosing options.
  • Approval based on FRONTIER clinical trial program showing significant reduction in annualised bleeding rates.
  • Novo Nordisk plans EU launch in early 2027, with additional regulatory reviews ongoing in the US and other markets.
  • FREHEMGO® is the first FVIIIa mimetic bispecific antibody with flexible dosing via a single-use pre-filled pen.

Novo Nordisk's FREHEMGO® approval marks a strategic win in the haemophilia A treatment space, where flexible dosing and inhibitor coverage are key differentiators. The approval positions Novo Nordisk to challenge Roche's emicizumab, leveraging clinical trial data that highlights strong bleed protection across patient demographics. The bi-weekly and monthly dosing options could enhance patient compliance and market adoption, particularly in a competitive landscape where convenience and efficacy are critical.

Regulatory Momentum
Whether the FDA and other global regulators will follow the EU's lead in approving FREHEMGO®, accelerating its market entry.
Market Penetration
The pace at which Novo Nordisk can launch and scale FREHEMGO® across Europe, competing with existing therapies like emicizumab.
Clinical Adoption
How healthcare providers and patients respond to the flexible dosing options, which could drive preference for FREHEMGO® over rivals.